Concepedia

David Vicente

DV

Statistics

Publications

20

Citations

8.6K

H-Index

17

Active since

2011

Affiliations

Hospital Universitario Virgen Macarena(Current)

AstraZeneca (United States)

AstraZeneca (United Kingdom)

The University of Sydney

Tennessee Oncology

David Vicente is an author at Hospital Universitario Virgen Macarena specializing in medicine, cancer therapeutics, and radiation oncology.

ORCID

Top concepts

Publications per year

2011–2023

20

Publications

20

Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

Scott Antonia, Augusto Villegas, Davey B. Daniel et al. · New England Journal of Medicine · 2017 · 4.4K citations · Full text

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

Scott Antonia, Augusto Villegas, Davey B. Daniel et al. · New England Journal of Medicine · 2018 · 2.7K citations · Full text

Comprehensive molecular characterization of mitochondrial genomes in human cancers

Yuan Yuan, Young Seok Ju, Young-Wook Kim et al. · Nature Genetics · 2020 · 489 citations · Full text

Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC

Jhanelle E. Gray, Augusto Villegas, Davey B. Daniel et al. · Journal of Thoracic Oncology · 2019 · 423 citations · Full text

Five-year survival outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC: An update from the PACIFIC trial.

David R. Spigel, Corinne Faivre‐Finn, Jhanelle E. Gray et al. · Journal of Clinical Oncology · 2021 · 98 citations

, , +16

1–5 of 20